Target site concentrations of ciprofloxacin after single intravenous and oral doses

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3724-3730

  Brunner, Martin ^a   Staß, Heino ^b   Möller, Jan Georg ^b   Schrolnberger, Claudia ^a   Erovic, Boban ^a   Hollenstein, Ursula ^a   Zeitlinger, Markus ^a   Georg Eichler, Hans ^a   Müller, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLISTER; BLOOD SAMPLING; CAPILLARY BLOOD; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SALIVA LEVEL; ENTEROBACTER; HUMAN; HUMAN EXPERIMENT; KLEBSIELLA PNEUMONIAE; MALE; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SKELETAL MUSCLE; STAPHYLOCOCCUS AUREUS; TISSUE DISTRIBUTION; VENOUS BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SALIVA;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SALIVA; TISSUE DISTRIBUTION;

EID: 0036896404     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3724-3730.2002     Document Type: Article

References (21)

1. Amodio-Groton, M., A. Madu, C. N. Madu, L. L. Briceland, M. Seligman, P. McMaster, and M. H. Miller. 1996. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: A pharmacoeconomic analysis. Ann. Pharmacother. 30:596-602.
2. Bannefeld, K. H., H. Stass, and G. Blaschke. 1997. Capillary electrophoresis with laser-induced fluorescence detection, an adequate alternative to high performance liquid chromatography, for the determination of ciprofloxacin and its metabolite desethyleneciprofloxacin in human plasma. J. Chromatogr. B 692:453-459.
3. Brunner, M., U. Hollenstein, S. Delacher, D. Jäger, R. Schmid, E. Lackner, A. Georgopoulos, H. G. Eichler, and M. Müller. 1999. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob. Agents Chemother. 43:1307-1309.
4. Carlier, M. B., B. Scorneaux, A. Zenebergh, J. F. Desnottes, and P. M. Tulkens. 1990. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J. Antimicrob. Chemother. 26(Suppl. B):27-39.
5. Davis, R., A. Markham, and J. A. Balfour. 1996. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51: 1019-1074.
6. Dudley, M. N., H. D. Mandler, D. Gilberd, J. Ericson, K. H. Mayer, and S. H. Zinner. 1987. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin: studies in vivo and in an in vitro dynamic model. Am. J. Med. 82(Suppl. 4A):363-368.
7. Echols, R. M. 1993. The selection of appropriate dosages for intravenous ciprofloxacin. J. Antimicrob. Chemother. 31:783-787.
8. Eichler, H. G., and M. Müller. 1998. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin. Pharmacokinet. 34:95-99.
9. Fass, R. J. 1986. Treatment of skin and soft tissue infections with oral ciprofloxacin. J. Antimicrob. Chemother. 18(Suppl. D):153-157.
10. Jones, R. N., E. N. Kehrberg, and M. E. Erwin. 1994. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn. Microbiol. Infect. Dis. 19:203-215.
11. Müller, M., R. Schmid, A. Georgopoulos, A. Buxbaum, C. Wasicek, and H. G. Eichler. 1995. Application of microdialysis to clinical pharmacokinetics in humans. Clin. Pharmacol. Ther. 57:371-380.
12. Müller, M., O. Haag, T. Burgdorff, A. Georgopoulos, W. Weninger, B. Jansen, G. Stanek, E. Agneter, H. G. Eichler, and H. Pehamberger. 1996. Characterization of peripheral compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob. Agents Chemother. 40:2703-2709.
13. Müller, M., M. Brunner, R. Schmid, E. M. Putz, A. Schmidberger, I. Wallner, and H. G. Eichler. 1998. Comparison of three different experimental methods for the assessment of peripheral pharmacokinetics in humans. Life Sci. 62:PL227-PL234.
14. Müller, M., M. Brunner, U. Hollenstein, C. Joukhadar, R. Schmid, E. Minar, H. Ehringer, and H. G. Eichler. 1999. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob. Agents Chemother. 43:2056-2058.
15. Paladino, A. 1999. Pharmacoeconomics of antimicrobial therapy. Am. J. Health-System Pharm. 56(Suppl. 3):S25-S28.
16. Smith, A., A. Weber, R. Pandher, J. Williams-Warren, M. L. Cohen, and B. Ramsey. 1997. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 25:106-108.
17. Stahle, L., P. Arner, and U. Ungerstedt. 1991. Drug distribution studies with microdialysis. III. Extracellular concentration of caffeine in adipose tissue in man. Life Sci. 49:1853-1858.
18. Thomson, C. 1999. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J. Antimicrob. Chemother. 43(Suppl. A):31-40.
19. Tulkens, P. M. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
20. Wilson, A. P. R., and R. N. Grüneberg. 1997. Ciprofloxacin: 10 Years of Clinical Experience. Maxim Medical, Magdalen Centre, The Oxford Science Park, Oxford, United Kingdom.
21. Zhai, S. Z., X. Wie, B. M. Parker, K. L. Kunze, and R. E. Vestal. 1996. Relation between plasma and saliva concentrations of enoxacin, ciprofloxacin, and theophylline. Ther. Drug Monit. 18:666-671.